Whaijen Soo, Ph.D. serves as Senior Vice President, Research and Development at Shire Human Genetic Therapies (HGT) and is responsible for overseeing HGT's strategic planning and growth and management of its research and development portfolio. Dr. Soo served as the Chief Scientific Officer and Member of Management Board of Jerini AG since October 2008. Prior to joining Shire HGT, he served as Senior Vice President of Medical Research at BiogenIdec, where he was responsible for the worldwide clinical development of all drugs in its portfolio. Before joining BiogenIdec, he spent eighteen years with Hoffmann La-Roche Inc., as Vice President and Head of Clinical Sciences in charge of worldwide clinical development of new anticancer drugs, antiviral and immunotherapies against AIDS and other viral diseases, as well as drugs used for transplantation. He has coordinated business and research strategic planning, as well as pharma portfolio management at Roche, and led the integration of clinical research organizations during Roche's acquisitions of Syntex and Bohringer-Mannheim. He serves as a Member of Interferon Advisory Board of Allozyne, Inc. Dr. Soo was a member of numerous public and trade committees, including Round Table on Research and Development of Drugs, Biologics, and Devices, Institute of Medicine, National Academy of Science, Board of Participants, Intercompany Collaborations on AIDS drug development, and Scientific Panel, American Foundation on AIDS Research. He is a Board member of Linden Technologies Inc. Dr. Soo earned a B.S. in Chemistry from the National Taiwan University and graduated with a Ph.D. in Biochemistry from the University of California at Berkeley, and his M.D. from the University of California at San Francisco Medical School and performed his Residency in Internal Medicine at Brigham and Woman's Hospital, Harvard Medical School.